<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738699</url>
  </required_header>
  <id_info>
    <org_study_id>MORAb003-003PR</org_study_id>
    <nct_id>NCT00738699</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer</brief_title>
  <acronym>FAR-122</acronym>
  <official_title>A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morphotek</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Morphotek</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to find out if paclitaxel works better when given together with
      an experimental drug called MORAb-003 (farletuzumab) or alone in patients with
      platinum-resistant or refractory relapsed ovarian cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety was assessed by the monitoring and recording of all adverse events (AEs), including
      drug hypersensitivity adverse events (DHAE), and serious adverse events (SAEs); clinical
      laboratory test (serum chemistry, hematology, urinalysis); tolerability (discontinuations,
      treatment delays, dose reductions); physical examinations (including vital signs assessment);
      12-lead electrocardiograms (ECG) obtained in triplicate and reviewed by independent blinded
      cardiologist, and Karnofsky's performance status.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study did not meet pre-specified criteria for continuation following interim futility analysis
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Date of Randomization to date of disease progression or death (whichever came first), assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
    <description>PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST), or death regardless of cause. If progression or death was not observed, the PFS time was censored at the date of the last tumor assessment without evidence of progression before the date of initiation of further antitumor treatment, or the cutoff date (whichever was earlier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Date of Randomization to date of death, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
    <description>OS was defined as the time (in months) from the date of randomization to the date of death, whatever the cause. If death was not observed for a participant, the survival time was censored on the last date the participant was known to be alive or the cutoff date, whichever was earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>Date of first study drug to disease progression/recurrence, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
    <description>BOR was defined as the percentage of participants having either a confirmed complete response (CR) or confirmed partial response (PR) using modified RECIST criteria by independent radiologist review. RECIST criteria was adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Tumor assessments performed up to the initiation of further antitumor treatment were considered. Target lesions selected for response assessment were measured using computed tomography (CT) or magnetic resonance imaging (MRI) scans then graded according to the modified RECIST criteria, adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Participants were assigned to one of the categories of change in disease state; CR, PR, progressive disease (PD), stable disease ( S)D, or not evaluable (NE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Date of Randomization to the first documentation of objective TR, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
    <description>TTR was derived for those participants with objective evidence of CR or PR, and was defined as the time (in months) from the date of randomization to the first documentation of object tumor response (TR). Analysis was based on the Kaplan-Meier estimated percentage of responders. This statistical analysis method measures the effect of study drug on tumor response over a period of time.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression Free Survival Based on Gynecologic Cancer InterGroup (GCIG)</measure>
    <time_frame>Length of study</time_frame>
    <description>Due to termination of the study, data were not collected and the outcome measure for PFS based on GCIG was not analyzed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serologic Response Rate</measure>
    <time_frame>Length of study</time_frame>
    <description>Due to termination of the study, data were not collected and the outcome measure for Serologic Response Rate was not analyzed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MORAb-003 (Farletuzumab) Plus Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Plus Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORAb-003 (farletuzumab)</intervention_name>
    <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline</intervention_name>
    <description>Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Paclitaxel (80 mg/m^2) was administered by IV infusion over 1 hour following administration of FAR.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-mucinous epithelial ovarian cancer, including primary peritoneal and
             fallopian tube malignancies, measurable by CT or MRI scan assessed within 4 weeks
             prior to study entry

          -  Must have evidence of relapse by CA-125 (2xUpper Limit of Normal) or radiographically
             within 6 months of most recent platinum-containing chemotherapy. At least one of the
             lines of chemotherapy must have included a taxane.

          -  Must have been treated with debulking surgery and at least one line platinum-based
             chemotherapy;

          -  Subjects may have received up to four additional lines of chemotherapy after they
             developed platinum-resistance.

          -  Subjects must be candidate for repeat paclitaxel treatment

        Exclusion Criteria:

          -  Clinical contraindications to use of paclitaxel, which include:

               1. persistent Grade 2 or greater peripheral neuropathy

               2. prior hypersensitivity reaction that persisted despite rechallenge with or
                  without desensitization or resulted in bronchospasm or hemodynamic instability or
                  was at least Grade 2 and resulted in medication discontinuation

          -  Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline
             carcinomas). Note: EOC with prior diagnosis of a low malignant potential tumor that
             has been surgically resected is acceptable provided the subject did

          -  Prior radiation therapy is excluded with the exception that it is allowable only if
             measurable disease for ovarian cancer is completely outside the radiation portal

          -  Known allergic reaction to a prior monoclonal antibody therapy or have any documented
             human anti-human antibody (HAHA).

          -  Previous treatment with MORAb-003 (farletuzumab).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monterey Bay Oncology</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Gynecologic Oncology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Specialists, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwartz Gynecologic Oncology, PLLC</name>
      <address>
        <city>Brightwaters</city>
        <state>New York</state>
        <zip>11718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arena Oncology Associates, PC</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hematology Oncology Associates, PA</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Beneficence Clinical Research, LLC</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Oncology &amp; Hematology PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital and Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Virginia Pelvic Surgery Associates</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burnside War Memorial Hospital, Inc.</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <zip>5064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital for Women</name>
      <address>
        <city>Heidelburg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Women's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of God Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Greninge Hospital</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataro</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Taulis</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <results_first_submitted>December 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <disposition_first_submitted>November 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 12, 2013</disposition_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>relapsed ovarian cancer</keyword>
  <keyword>refractory ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
          <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Normal Saline) Plus Paclitaxel</title>
          <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Treated</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation of study by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat population included, the primary population for the evaluation of efficacy, was defined as all participant who were randomly assigned to test article, analyzed by the treatment assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
          <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Normal Saline) Plus Paclitaxel</title>
          <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="415"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="10.74"/>
                    <measurement group_id="B2" value="61.2" spread="9.44"/>
                    <measurement group_id="B3" value="61.0" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST), or death regardless of cause. If progression or death was not observed, the PFS time was censored at the date of the last tumor assessment without evidence of progression before the date of initiation of further antitumor treatment, or the cutoff date (whichever was earlier).</description>
        <time_frame>Date of Randomization to date of disease progression or death (whichever came first), assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
        <population>Intent-To-Treat (ITT) population included all participants who were randomly assigned to study drug, analyzed by treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST), or death regardless of cause. If progression or death was not observed, the PFS time was censored at the date of the last tumor assessment without evidence of progression before the date of initiation of further antitumor treatment, or the cutoff date (whichever was earlier).</description>
          <population>Intent-To-Treat (ITT) population included all participants who were randomly assigned to study drug, analyzed by treatment assignment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.3" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.3" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8360</p_value>
            <p_value_desc>One-sided log rank test stratified by route of administration for primary chemotherapy (intraperitoneal vs intravenous) and geographic region (North America, Europe, and other participating countries).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>Stratified as described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time (in months) from the date of randomization to the date of death, whatever the cause. If death was not observed for a participant, the survival time was censored on the last date the participant was known to be alive or the cutoff date, whichever was earlier.</description>
        <time_frame>Date of Randomization to date of death, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
        <population>ITT population included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time (in months) from the date of randomization to the date of death, whatever the cause. If death was not observed for a participant, the survival time was censored on the last date the participant was known to be alive or the cutoff date, whichever was earlier.</description>
          <population>ITT population included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.3" upper_limit="12.7"/>
                    <measurement group_id="O2" value="13.1" lower_limit="10.3" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7568</p_value>
            <p_value_desc>One-sided log rank test stratified by route of administration for primary chemotherapy and geographic region.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Stratified as described above</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response</title>
        <description>BOR was defined as the percentage of participants having either a confirmed complete response (CR) or confirmed partial response (PR) using modified RECIST criteria by independent radiologist review. RECIST criteria was adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Tumor assessments performed up to the initiation of further antitumor treatment were considered. Target lesions selected for response assessment were measured using computed tomography (CT) or magnetic resonance imaging (MRI) scans then graded according to the modified RECIST criteria, adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Participants were assigned to one of the categories of change in disease state; CR, PR, progressive disease (PD), stable disease ( S)D, or not evaluable (NE).</description>
        <time_frame>Date of first study drug to disease progression/recurrence, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
        <population>ITT population included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response</title>
          <description>BOR was defined as the percentage of participants having either a confirmed complete response (CR) or confirmed partial response (PR) using modified RECIST criteria by independent radiologist review. RECIST criteria was adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Tumor assessments performed up to the initiation of further antitumor treatment were considered. Target lesions selected for response assessment were measured using computed tomography (CT) or magnetic resonance imaging (MRI) scans then graded according to the modified RECIST criteria, adjusted based on current medical practices and on possible differences between ovarian cancer and other solid tumors. Participants were assigned to one of the categories of change in disease state; CR, PR, progressive disease (PD), stable disease ( S)D, or not evaluable (NE).</description>
          <population>ITT population included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0399</p_value>
            <p_value_desc>Compared the ratio of complete or partial responders in the two arms. Stratified by route of administration for first line therapy and geographic region as specified at baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
            <estimate_desc>(FAR + Paclitaxel) minus (Placebo + Paclitaxel). Confidence interval based on a normal approximation to the binomial distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Response (TTR)</title>
        <description>TTR was derived for those participants with objective evidence of CR or PR, and was defined as the time (in months) from the date of randomization to the first documentation of object tumor response (TR). Analysis was based on the Kaplan-Meier estimated percentage of responders. This statistical analysis method measures the effect of study drug on tumor response over a period of time.</description>
        <time_frame>Date of Randomization to the first documentation of objective TR, assessed up to study termination (28 Nov 2011), or up to approximately 2 years 10 months</time_frame>
        <population>ITT population (Responders only) included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Response (TTR)</title>
          <description>TTR was derived for those participants with objective evidence of CR or PR, and was defined as the time (in months) from the date of randomization to the first documentation of object tumor response (TR). Analysis was based on the Kaplan-Meier estimated percentage of responders. This statistical analysis method measures the effect of study drug on tumor response over a period of time.</description>
          <population>ITT population (Responders only) included all participants who were randomly assigned to study drug and analyzed by the treatment assigned.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.6" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.6" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Progression Free Survival Based on Gynecologic Cancer InterGroup (GCIG)</title>
        <description>Due to termination of the study, data were not collected and the outcome measure for PFS based on GCIG was not analyzed.</description>
        <time_frame>Length of study</time_frame>
        <population>Due to termination of the study, data were not collected and the outcome measure for PFS based on GCIG was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Based on Gynecologic Cancer InterGroup (GCIG)</title>
          <description>Due to termination of the study, data were not collected and the outcome measure for PFS based on GCIG was not analyzed.</description>
          <population>Due to termination of the study, data were not collected and the outcome measure for PFS based on GCIG was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serologic Response Rate</title>
        <description>Due to termination of the study, data were not collected and the outcome measure for Serologic Response Rate was not analyzed.</description>
        <time_frame>Length of study</time_frame>
        <population>Due to termination of the study, data were not collected and the outcome measure for Serologic Response Rate was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
            <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline) Plus Paclitaxel</title>
            <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Serologic Response Rate</title>
          <description>Due to termination of the study, data were not collected and the outcome measure for Serologic Response Rate was not analyzed.</description>
          <population>Due to termination of the study, data were not collected and the outcome measure for Serologic Response Rate was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time the participant signed the study informed consent form until 30 days after the last dose of study drug (FAR or placebo), for up to approximately 3 years.</time_frame>
      <desc>Safety Analysis Set was defined as all randomized participants who received any dose of FAR or placebo, analyzed according to the test article received. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 was used to grade severity of AEs. Treatment-emergent adverse events were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>MORAb-003 (Farletuzumab) Plus Paclitaxel</title>
          <description>Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Normal Saline) Plus Paclitaxel</title>
          <description>An equivalent volume of placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles. Paclitaxel (80 mg/m^2) was administered weekly by IV infusion over 1 hour following administration of FAR. During the 4-week cycle, Week 4 was to be a rest period with no study treatment (test article or paclitaxel) administered. All participants were required to be premedicated with steroids before paclitaxel administration, and with acetaminophen (650 mg orally) or clinically equivalent per clinic routine within 4 hours prior to test article infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Select</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Anaemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Colonic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Large Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Colonic Pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Faecal Volume Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Faecal Volume Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oesophageal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rectourethral Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Short-Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Generalised Oedema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Cholecystitis Acute</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Cellulitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bacterial Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Candida Sepsis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Clostridium Difficle Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Incision Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Infectious Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Klebsiella Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pelvic Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Pneumonia bacterial</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Hypomagnesaemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Hypophagia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Muscle Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Systemic Lupus Erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Oncologic Complication</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tumour Associated Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Brain Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Encephelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Mononeuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephelopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Mental Status Change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bladder Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Pulmonary Embolism</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="MedDra 14.1">Pneumonitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatits Exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Skin Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Select</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Small intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroresophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nasopharyngitits</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Neuropathy Peripheral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 14.1">Alopecia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>This study was prematurely terminated by the sponsor following results of the preplanned futility analysis showing the study was unlikely to meet its statistically-defined coprimary endpoints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai Inc.</organization>
      <phone>1-888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

